论文部分内容阅读
目的探讨急性冠脉综合征患者及其服用阿司匹林前后血小板表面糖蛋白的变化及其意义。方法采用流式细胞仪(FCM)测定急性冠脉综合征患者阿司匹林治疗前后的全血中血小板表面糖蛋白(CD62p/PAC-1)的表达率,采用自身对照分析阿司匹林对血小板表面糖蛋白的影响。结果急性冠脉综合征组治疗前的血小板表面糖蛋白PAC-1、CD62p的表达率分别为(10.36±6.15)%和(10.72±7.12)%,较健康对照组明显升高(P<0.001),经以阿司匹林为基础的抗血小板治疗后CD62p、PAC-1的表达率下降至(4.32±2.08)%和(4.90±2.37)%,(P<0.001),但仍高于健康对照组。结论 CD62p和PAC-1是血小板活化的敏感和特异指标,且相关性良好,阿司匹林能够抑制血小板表面糖蛋白的表达,从而抑制血小板活化,抑制血栓形成。
Objective To investigate the changes of platelet surface glycoprotein in patients with acute coronary syndrome and before and after taking aspirin and its significance. Methods The expression of platelet surface glycoprotein (CD62p / PAC-1) in whole blood of patients with acute coronary syndrome before and after aspirin treatment was determined by flow cytometry (FCM). The effect of aspirin on platelet surface glycoprotein . Results The expression of platelet surface glycoproteins PAC-1 and CD62p before treatment in ACS group were (10.36 ± 6.15)% and (10.72 ± 7.12)%, respectively, which were significantly higher than those in healthy controls (P <0.001) , The expression of CD62p and PAC-1 decreased to (4.32 ± 2.08)% and (4.90 ± 2.37)%, respectively (P <0.001) after aspirin-based antiplatelet therapy, but still higher than that of the healthy control group. Conclusion CD62p and PAC-1 are sensitive and specific indicators of platelet activation, and good correlation, aspirin can inhibit the expression of platelet surface glycoprotein, thereby inhibiting platelet activation, inhibiting thrombosis.